Ospemifene (Osphena): Uses, Dosage, Side Effects, and How It Compares to Other Treatments for Women's Sexual Health

What is ospemifene and what does it treat?

Ospemifene is a third-generation SERM that selectively activates estrogen receptors in vaginal tissue. The FDA approved it in February 2013 for moderate-to-severe dyspareunia, and expanded the label in 2014 to include moderate-to-severe vaginal dryness, both caused by genitourinary syndrome of menopause (GSM). Unlike systemic hormone therapy, it does not require progesterone co-administration for endometrial protection at the 60 mg dose studied in trials, because its uterine activity appears to be largely neutral or weakly antagonistic rather than strongly proliferative.

GSM affects an estimated 27 to 84 percent of postmenopausal women, yet fewer than 25 percent seek treatment, partly due to embarrassment and partly because many do not realize that effective prescription options exist beyond lubricants. Vaginal pH rises above 5.0, epithelial cells thin, and collagen density drops when estrogen withdrawal occurs, producing dryness, burning, discharge changes, and pain with penetration. Ospemifene addresses these changes by activating estrogen receptor-alpha in vaginal and urethral epithelium, which restores superficial cell maturation and lowers pH.

The Menopause Society (formerly NAMS) 2023 position statement lists ospemifene as a first-line prescription option for women with bothersome GSM symptoms who prefer oral therapy over vaginal administration. [1]

How ospemifene works: SERM pharmacology explained

Selective estrogen receptor modulators bind the same receptor as estrogen but produce tissue-specific effects depending on the co-activators and co-repressors present in each cell type. Ospemifene acts as an agonist in vaginal epithelium, a partial agonist or neutral entity in bone, and an antagonist in breast tissue, which is the SERM profile that makes it clinically attractive for postmenopausal women.

Animal carcinogenicity data and the clinical trial program show no increase in mammary tumor formation. The drug's effect on the endometrium has been studied with transvaginal ultrasound and biopsy: in a 52-week safety study, endometrial thickness increased by a mean of 0.37 mm in the ospemifene group versus 0.10 mm with placebo, a small and clinically monitored difference, with no cases of endometrial hyperplasia or carcinoma observed. [2]

Pharmacokinetically, ospemifene is absorbed rapidly, reaches peak plasma concentration (Cmax) in approximately 2 hours, and has an elimination half-life of roughly 26 hours, supporting once-daily dosing. Taking the tablet with a high-fat meal increases bioavailability by approximately 2.5-fold, so consistent administration with food is recommended to reduce variability.

Clinical trial evidence: what the Phase 3 data actually showed

Three key Phase 3 trials (Studies 15-50310, 15-50311, and 15-50821) enrolled postmenopausal women with moderate-to-severe GSM symptoms over 12 weeks. Ospemifene 60 mg produced statistically significant improvements across the co-primary endpoints compared with placebo. [3]

Across the trials:

• The percentage of superficial vaginal cells (maturation index) increased by a mean of 10.8 percentage points with ospemifene versus 0.9 points with placebo (P<0.001).
• Vaginal pH fell by a mean of 0.94 units with ospemifene versus 0.28 units with placebo (P<0.001).
• In the dyspareunia-primary trial, 36.1% of ospemifene patients reported their most bothersome symptom as absent or mild at week 12, versus 24.2% on placebo (P<0.001).
• In the vaginal dryness-primary trial, 30.3% of ospemifene patients reported dryness absent or mild at week 12, versus 21.0% on placebo (P<0.05).

The 52-week extension study confirmed durable benefit with no new safety signals. Hot flashes occurred in 7.5% of ospemifene-treated women versus 2.6% receiving placebo, a real adverse effect worth discussing with patients before prescribing.

Dosing, administration, and practical prescribing guidance

The approved dose is ospemifene 60 mg by mouth once daily with food. No dose titration is needed. Missed doses should be taken as soon as remembered unless it is nearly time for the next dose.

Women with severe hepatic impairment (Child-Pugh C) should not receive ospemifene because hepatic metabolism via CYP3A4 and CYP2C9 is the primary elimination pathway. Concurrent use of rifampin (a strong CYP inducer) reduces ospemifene exposure by approximately 80%; concurrent use of fluconazole (a strong CYP inhibitor) increases exposure by approximately 2.7-fold. Both combinations require careful clinical judgment and may necessitate alternative therapy.

Routine endometrial monitoring with annual ultrasound is prudent, though no specific mandated monitoring interval is defined in the prescribing information. Women who experience unscheduled vaginal bleeding while on ospemifene should have prompt endometrial evaluation.

Ospemifene is contraindicated in women with:

• Undiagnosed abnormal uterine bleeding
• Known or suspected estrogen-dependent neoplasia
• Active deep vein thrombosis, pulmonary embolism, or a history of these conditions
• Active arterial thromboembolic disease (stroke, myocardial infarction)
• Known hypersensitivity to ospemifene or any excipient

Ospemifene vs. vaginal estradiol: which treats GSM better?

Vaginal estradiol is the most prescribed treatment for GSM worldwide and remains the comparator against which ospemifene is most often measured. Both improve the maturation index, reduce vaginal pH, and reduce dyspareunia severity, but they differ in route, systemic absorption, and patient preference.

Vaginal estradiol products include Estrace cream (0.01% estradiol), Vagifem and Yuvafem tablets (10 mcg estradiol), and the Estring ring (7.5 mcg/day). Systemic estradiol absorption from the 10 mcg tablet is minimal: serum estradiol levels remain within the postmenopausal range (<20 pg/mL) in most women, which is why major guidelines classify low-dose vaginal estradiol as a locally acting product that does not require routine progestogen co-administration in women with an intact uterus. [4]

A 2018 network meta-analysis published in Menopause (N=4,510 across 30 trials) found that vaginal estradiol tablets and ospemifene produced comparable improvements in dyspareunia severity, with no statistically significant difference in efficacy between them. Women who strongly prefer oral administration or who have anatomical difficulty with vaginal applicators may find ospemifene's pill format significantly more practical. Women who want the lowest possible systemic exposure, however, may prefer the 10 mcg vaginal tablet or the Estring.

Ospemifene vs. vaginal DHEA (prasterone/Intrarosa): a different mechanism

Prasterone, sold as Intrarosa, is an intravaginal DHEA (dehydroepiandrosterone) suppository approved by the FDA in November 2016 for moderate-to-severe dyspareunia due to GSM. [5] The dose is one 6.5 mg suppository inserted vaginally each evening.

Prasterone works by a different mechanism than either estrogens or SERMs. Vaginal epithelial cells contain the full enzymatic machinery to convert DHEA into estrogens and androgens locally. This intracrinology means the tissue receives both estrogen receptor and androgen receptor stimulation without meaningful rises in serum sex hormone levels, because the hormones made locally are further metabolized within the same cells.

In the Phase 3 AMETHYST trial (N=1,492 to 52 weeks), prasterone 6.5 mg significantly improved all four co-primary endpoints versus placebo: superficial cell percentage, parabasal cell percentage, vaginal pH, and self-assessed dyspareunia severity. [6] Serum estradiol remained within postmenopausal range throughout, which is relevant for women with estrogen-sensitive cancer histories.

Head-to-head data between ospemifene and prasterone are not currently available from a randomized controlled trial. Clinically, prasterone may be preferred in women with prior breast cancer where SERM effects are uncertain, though evidence in this population for either drug is limited.

Ospemifene vs. flibanserin (Addyi): treating different problems

Flibanserin (Addyi) addresses hypoactive sexual desire disorder (HSDD), a distinct condition from GSM. It is approved for premenopausal women with HSDD and works centrally as a 5-HT1A agonist and 5-HT2A antagonist to shift neurotransmitter balance toward dopaminergic and noradrenergic signaling in the prefrontal cortex. The dose is 100 mg orally at bedtime. [7]

The two drugs treat different diagnoses. A postmenopausal woman whose primary complaint is pain with intercourse due to vaginal atrophy needs ospemifene (or vaginal estradiol or prasterone). A premenopausal woman whose primary complaint is absent or reduced sexual desire with no physical cause needs flibanserin. Some women have both low desire and GSM, requiring individualized treatment planning.

Flibanserin's Phase 3 program (BEGONIA, SNOWDROP, VIOLET) showed a mean increase of 0.3 to 1.0 satisfying sexual events per month versus placebo, statistically significant but modest in absolute terms. [8] The most restrictive aspect of flibanserin is its REMS program, which prohibits concurrent alcohol use due to the risk of severe hypotension and syncope.

Ospemifene vs. bremelanotide (Vyleesi/PT-141): on-demand desire vs. structural repair

Bremelanotide (Vyleesi, formerly known as PT-141) is an FDA-approved melanocortin receptor agonist for HSDD in premenopausal women. It is self-administered as a 1.75 mg subcutaneous injection in the abdomen or thigh 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than one dose per week advised due to blood pressure effects. [9]

Like flibanserin, bremelanotide treats low desire, not structural vaginal changes. The Phase 3 trials (RECONNECT A and B, combined N=1,267) showed a mean increase of 0.5 satisfying sexual events per month and a mean 1.2-point improvement on the Female Sexual Distress Scale-Desire subscale compared with placebo. [10] Transient nausea occurred in approximately 40% of bremelanotide users and hyperpigmentation in approximately 1%, the latter being a melanocortin-related effect that resolved after stopping treatment.

Comparing bremelanotide to ospemifene is comparing apples to oranges in clinical terms: one is an on-demand desire drug for premenopausal women; the other is a daily tissue-restorative SERM for postmenopausal women. Prescribers occasionally encounter women with concurrent diagnoses of HSDD and GSM, in which case combination therapy with a GSM agent plus a central desire agent may be appropriate after careful benefit-risk assessment.

Side effects and safety: what patients need to know

The most common adverse effects of ospemifene in Phase 3 trials were:

| Adverse Effect | Ospemifene 60 mg | Placebo | |---|---|---| | Hot flashes | 7.5% | 2.6% | | Vaginal discharge | 3.8% | 0.3% | | Muscle spasms | 3.2% | 0.9% | | Genital discharge | 1.3% | 0.1% |

Venous thromboembolism (VTE) was not observed in Phase 3 trials, but the SERM class carries a VTE signal based on data from tamoxifen and raloxifene. The ospemifene prescribing information carries a boxed warning regarding this risk and instructs prescribers to discontinue the drug at least 4 to 6 weeks before prolonged immobilization. Women with active or prior VTE should not receive ospemifene.

The breast cancer boxed warning notes that ospemifene has not been studied in women with breast cancer and should be used with caution in women with known or suspected breast cancer.

Cardiovascular: a 52-week study in 426 women showed no increase in serious cardiovascular adverse events, though the trial was not powered to detect rare events. [11]

The HealthRX decision framework: choosing the right GSM or sexual health treatment

The following framework is used by the HealthRX medical team to guide treatment selection during consultations. It is not a substitute for individual clinical evaluation.

Step 1: Identify the primary complaint.

• Pain with intercourse or vaginal dryness without desire complaint: go to Step 2.
• Low sexual desire (absent or reduced, causing distress) in a premenopausal woman: consider flibanserin or bremelanotide.
• Both pain and low desire in a postmenopausal woman: treat GSM first; reassess desire after 12 weeks.

Step 2: Assess route preference and contraindications.

• Prefers oral route, no VTE history, no undiagnosed bleeding: ospemifene 60 mg daily with food is appropriate.
• Prefers local therapy, lowest systemic exposure: vaginal estradiol 10 mcg tablet or Estring ring.
• Prior breast cancer, or wants androgen receptor stimulation plus estrogen receptor stimulation locally: prasterone 6.5 mg intravaginal nightly.
• Estrogen-sensitive malignancy confirmed, local therapy not acceptable: discuss non-hormonal options (lubricants, moisturizers, CO2 laser if available) with oncology input.

Step 3: Set a 12-week reassessment.

• Evaluate symptom burden using a validated scale (FSFI or DYSIS).
• If partial response, confirm daily dosing with food.
• If no response after 12 weeks and adherence is confirmed, switch to an alternative GSM therapy.

Step 4: Annual safety monitoring on ospemifene.

• Transvaginal ultrasound if unscheduled bleeding occurs.
• Review VTE risk factors annually.
• Reassess continued need if patient enters extended remission of GSM symptoms.

Who should not take ospemifene?

Absolute contraindications, per the FDA-approved labeling:

1. Active or prior VTE or arterial thromboembolic event.
2. Undiagnosed abnormal uterine bleeding.
3. Known or suspected estrogen-dependent neoplasia.
4. Pregnancy (ospemifene may cause fetal harm based on animal data).
5. Hypersensitivity to ospemifene.

Women with a history of breast cancer, those on tamoxifen (SERM-on-SERM effect), and those on strong CYP3A4 or CYP2C9 inhibitors require careful pharmacological review before starting ospemifene.

Accessing ospemifene: cost, generics, and telehealth options

The brand-name Osphena carries a retail price of approximately $400 to $500 per 30-tablet supply without insurance. Generic ospemifene became available in the United States in 2023, dropping the price to roughly $80 to $150 per month at major pharmacies, with GoodRx coupons occasionally reducing this further.

A valid prescription is required. Telehealth platforms, including HealthRX, can connect patients with licensed clinicians who can evaluate whether ospemifene is appropriate, prescribe electronically, and monitor progress remotely. The 2023 NAMS position statement specifically notes that telemedicine is an acceptable and effective care delivery model for GSM management.

Women who have not had a gynecologic exam in more than 3 years, or who have undiagnosed vaginal bleeding, should have an in-person evaluation before starting any GSM therapy.

Managing hot flashes that occur on ospemifene

Because ospemifene produces hot flashes in roughly 7.5% of users, a subset of postmenopausal women find this side effect limits tolerability. Options include:

• Waiting 4 to 6 weeks: hot flashes from ospemifene tend to decrease as the body adjusts.
• Non-hormonal pharmacotherapy: the FDA approved fezolinetant (Veozah) 45 mg once daily in May 2023 for moderate-to-severe vasomotor symptoms; it works via neurokinin 3 receptor antagonism and does not interact with ospemifene's pathway.
• Switching routes: women who develop hot flashes on oral ospemifene and need GSM treatment may tolerate low-dose vaginal estradiol better because systemic absorption is negligible at the 10 mcg dose.

Monitoring estrogen-dependent endpoints during long-term use

Women taking ospemifene for more than 12 months benefit from systematic monitoring. The 2023 NAMS GSM position statement [1] specifies that "treatment of GSM should continue as long as symptoms are bothersome, with periodic reassessment of benefit and risk." No defined upper duration limit exists in the prescribing information, but the longest controlled trial data available are 52 weeks.

Annual assessment should include:

• Review of new cardiovascular or thromboembolic risk factors.
• Symptom reassessment using a standardized tool.
• Endometrial evaluation if unscheduled bleeding develops.
• Breast cancer screening per age-appropriate guidelines (mammography annually starting at age 40, per American Cancer Society guidelines).